Anti-MDA5 Antibody-positive Dermatomyositis with Rapidly Progressive Interstitial Pneumonia Presenting with Nephrotic Syndrome during Treatment with Corticosteroids and Cyclosporine

Intern Med. 2022 Jul 1;61(13):2007-2012. doi: 10.2169/internalmedicine.8311-21. Epub 2021 Nov 13.

Abstract

A 50-year-old Japanese woman with anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 antibody)-positive dermatomyositis presenting with rapidly progressive interstitial pneumonia was treated with corticosteroids and cyclosporine. She developed nephrotic syndrome during the treatment regimen with corticosteroids and cyclosporine. A kidney biopsy revealed a thrombotic microangiopathy (TMA) glomerular lesion. Anti-MDA5 antibody-positive dermatomyositis is prone to severe interstitial lung disease (ILD) and is often exacerbated and refractory to treatment. Renal symptoms might be due to TMA of the kidney, and this may be a sign that more intensive treatment is needed. Patients sometimes develop acute kidney injury, which may be due to the TMA.

Keywords: anti-MDA5 antibody-positive dermatomyositis; cyclosporine; nephrotic syndrome; rapidly progressive interstitial pneumonia; thrombotic microangiopathy.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Autoantibodies
  • Cyclosporine / therapeutic use
  • Dermatomyositis* / complications
  • Dermatomyositis* / diagnosis
  • Dermatomyositis* / drug therapy
  • Female
  • Humans
  • Interferon-Induced Helicase, IFIH1
  • Lung Diseases, Interstitial* / complications
  • Lung Diseases, Interstitial* / drug therapy
  • Middle Aged
  • Nephrotic Syndrome* / complications
  • Nephrotic Syndrome* / drug therapy

Substances

  • Adrenal Cortex Hormones
  • Autoantibodies
  • Cyclosporine
  • Interferon-Induced Helicase, IFIH1